{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:47:07Z","timestamp":1792032427621,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec><jats:title>Purpose:<\/jats:title><jats:p>To investigate whether anti\u2013vascular endothelial growth factor (anti-VEGF) for diabetic macular edema or proliferative diabetic retinopathy (PDR) increases the risk of traction retinal detachment (TRD) among eyes with PDR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Pooled analysis of PDR eyes from Protocols I, J, N, S, or T with Early Treatment Diabetic Retinopathy Study level \u226561 (prompt vitrectomy was not planned) randomly assigned to the control group (laser photocoagulation, sham, or intravitreal saline; 396 eyes) or anti-VEGF (487 eyes). The primary outcome was investigator-identified TRD within 1 year of randomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The 1-year cumulative probability of TRD was 6.8% (95% confidence interval: 4.6%\u20139.9%, 25 events) in control-group eyes and 4.8% (95% confidence interval: 3.2%\u20137.3%, 22 events) in anti-VEGF group eyes (hazard ratio = 0.95 [95% confidence interval: 0.54\u20131.66,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.86]). The cumulative probability of vitrectomy for TRD was 4.4% (16 events) in control-group eyes and 2.2% (9 events) in anti-VEGF group eyes (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.19). Percentage with TRD and vitrectomy for TRD were similar within strata of diabetic retinopathy severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>These findings do not support the hypothesis that anti-VEGF therapy for diabetic macular edema or PDR increases the risk of TRD among eyes with PDR similar to those enrolled in five DRCR Retina Network protocols for which prompt vitrectomy was not planned.<\/jats:p><\/jats:sec>","DOI":"10.1097\/iae.0000000000002633","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T14:47:39Z","timestamp":1569336459000},"page":"1021-1028","source":"Crossref","is-referenced-by-count":30,"title":["ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY"],"prefix":"10.1097","volume":"40","author":[{"given":"Neil M.","family":"Bressler","sequence":"first","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley T.","family":"Beaulieu","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Bressler","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Glassman","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Michele","family":"Melia","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Jampol","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag D.","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Retina Research Center, Austin, Texas;"},{"name":"Dell Medical School, University of Texas at Austin, Austin, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[{"name":"Atlantis Eye Care, Huntington Beach, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Velez","sequence":"additional","affiliation":[{"name":"Valley Eye Physicians and Surgeons, Ayer, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Sun","sequence":"additional","affiliation":[{"name":"Harvard Department of Ophthalmology, Joslin Diabetes Center, Beetham Eye Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DRCR Retina Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"1695.e1691","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R6-20230817","first-page":"77","article-title":"Intravitreal bevacizumab therapy for the treatment of ROP","author":"Chan","year":"2011","journal-title":"Retina"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"2304.e2303","DOI":"10.1016\/j.ophtha.2011.05.015","article-title":"Retinal detachment after bevacizumab","volume":"118","author":"Arevalo","year":"2011","journal-title":"Ophthalmology"},{"key":"R8-20230817","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","year":"2010","journal-title":"Ophthalmology"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","article-title":"Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation","volume":"31","author":"Googe","year":"2011","journal-title":"Retina"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","article-title":"Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy","volume":"131","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R12-20230817","first-page":"823","article-title":"Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy","volume":"98","year":"1991","journal-title":"ETDRS report number 12. Ophthalmology"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2016.12.005","article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab","volume":"124","author":"Bressler","year":"2017","journal-title":"Ophthalmology"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaophthalmol.2014.1698","article-title":"Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema","volume":"132","author":"Bressler","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaophthalmol.2014.1698","article-title":"Reproducibility of spectral\u2010domain optical coherence tomography retinal thickness measurements and conversion to equivalent time\u2010domain metrics in diabetic macular edema","volume":"132","author":"Bressler","year":"2014","journal-title":"JAMA Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T23:36:48Z","timestamp":1721777808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002633"}},"subtitle":["Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002633","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}